Literature DB >> 10899444

Phenotypic manifestations associated with CAG-repeat expansion in the androgen receptor gene in male patients and heterozygous females: a clinical and molecular study of 30 families.

C Mariotti1, B Castellotti, D Pareyson, D Testa, M Eoli, C Antozzi, V Silani, R Marconi, F Tezzon, G Siciliano, C Marchini, C Gellera, S D Donato.   

Abstract

Spinal and bulbar muscular atrophy (Kennedy disease) is an adult form of X-linked motor neuron disease caused by the expansion of a polymorphic CAG-repeat sequence in the first exon of the androgen receptor gene. We studied clinical and molecular features of 36 patients and 19 heterozygous females. Phenotypic manifestations and disease severity broadly varied among our spinal and bulbar muscular atrophy patients. The size of CAG expansion significantly influences the age of disease onset, but neither clinical features nor disease severity. The majority of carrier women presented signs of chronic denervation at neurophysiological examination and, in three cases, low-amplitude sensory action potentials were recorded. Notably, a few women developed mild signs of bulbar motor neuron impairment later in life. The identification of a large number of patients by the use of the molecular test further supports the hypothesis that Kennedy disease had been previously underdiagnosed, probably because of the great variability of clinical presentation. Although an early diagnosis may not be crucial for treatment, given the lack of effective therapy, the molecular testing can be of great relevance for disease prognosis and genetic counseling.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10899444     DOI: 10.1016/s0960-8966(99)00132-7

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  30 in total

Review 1.  Onset Manifestations of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease).

Authors:  Josef Finsterer; Gianni Soraru
Journal:  J Mol Neurosci       Date:  2015-10-19       Impact factor: 3.444

2.  Recovery of function in a myogenic mouse model of spinal bulbar muscular atrophy.

Authors:  Jamie A Johansen; Zhigang Yu; Kaiguo Mo; D Ashley Monks; Andrew P Lieberman; S Marc Breedlove; Cynthia L Jordan
Journal:  Neurobiol Dis       Date:  2008-12-31       Impact factor: 5.996

3.  Highly skewed inactivation of the wild-type X-chromosome in asymptomatic female carriers of spinal and bulbar muscular atrophy (Kennedy's disease).

Authors:  C Paradas; F Solano; F Carrillo; C Fernández; J Bautista; E Pintado; M Lucas
Journal:  J Neurol       Date:  2008-05-02       Impact factor: 4.849

4.  [Motor neuron diseases].

Authors:  S Petri; T Meyer
Journal:  Nervenarzt       Date:  2011-06       Impact factor: 1.214

5.  Analysis of inconsistencies in terminology of spinal and bulbar muscular atrophy and its effect on retrieval of research.

Authors:  Shelley Arvin
Journal:  J Med Libr Assoc       Date:  2013-04

6.  Androgen receptors in muscle fibers induce rapid loss of force but not mass: implications for spinal bulbar muscular atrophy.

Authors:  Kentaro Oki; Robert W Wiseman; S Marc Breedlove; Cynthia L Jordan
Journal:  Muscle Nerve       Date:  2013-04-30       Impact factor: 3.217

Review 7.  Pathogenic mechanisms and therapeutic strategies in spinobulbar muscular atrophy.

Authors:  Jason P Chua; Andrew P Lieberman
Journal:  CNS Neurol Disord Drug Targets       Date:  2013-12       Impact factor: 4.388

Review 8.  Diagnostic Clinical, Electrodiagnostic and Muscle Pathology Features of Spinal and Bulbar Muscular Atrophy.

Authors:  Manu E Jokela; Bjarne Udd
Journal:  J Mol Neurosci       Date:  2015-11-16       Impact factor: 3.444

9.  Review of Spinal Muscular Atrophy (SMA) for Prenatal and Pediatric Genetic Counselors.

Authors:  Amanda Carré; Candice Empey
Journal:  J Genet Couns       Date:  2015-08-08       Impact factor: 2.537

Review 10.  Spinal and bulbar muscular atrophy: ligand-dependent pathogenesis and therapeutic perspectives.

Authors:  Masahisa Katsuno; Hiroaki Adachi; Fumiaki Tanaka; Gen Sobue
Journal:  J Mol Med (Berl)       Date:  2004-02-27       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.